[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100635648":3},{"organization":4,"armGroups":7,"interventions":17,"overallOfficials":10,"centralContacts":10,"locations":10,"responsibleParty":23,"collaborators":10,"id":27,"slug":28,"hasResults":29,"nctId":30,"briefTitle":31,"officialTitle":32,"acronym":10,"eligibilityCriteria":33,"healthyVolunteers":29,"sex":34,"minAge":10,"maxAge":10,"enrollmentInfo":35,"targetDuration":38,"studyType":39,"phases":10,"briefSummary":40,"conditions":41,"keywords":10,"overallStatus":43,"whyStopped":10,"lastUpdateSubmitDate":44,"lastUpdatePostDateStruct":45,"startDateStruct":48,"completionDateStruct":50,"leadSponsor":52,"locationsCount":10},{"fullName":5,"class":6},"First Affiliated Hospital, Sun Yat-Sen University","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Combined Therapy Group",null,"Patients receiving autologous epidermal cell suspension sprayed onto the wound bed immediately after dermabrasion or surgical debridement, followed by coverage with porcine xenograft as a temporary biological dressing.",[13],"Procedure: Autologous Epidermal Cell Suspension",{"label":15,"type":10,"description":16,"interventionNames":10},"Conventional Treatment Group","Patients receiving conventional treatment after dermabrasion or surgical debridement without autologous epidermal cell suspension, including but not limited to: porcine xenograft alone, autologous skin grafting, or standard dressing changes.",[18],{"type":19,"name":20,"description":21,"armGroupLabels":22,"otherNames":10},"PROCEDURE","Autologous Epidermal Cell Suspension","A suspension of viable epidermal cells (including basal cells, epidermal stem cells, keratinocytes, melanocytes, and fibroblasts) isolated from a small sample of the patient's own skin. The suspension is sprayed onto the debrided wound bed to promote re-epithelialization.",[9],{"type":24,"investigatorFullName":25,"investigatorTitle":26,"investigatorAffiliation":5,"oldNameTitle":10,"oldOrganization":10},"PRINCIPAL_INVESTIGATOR","Hu Zhicheng","Professor","100635648","cell-suspension-with-biologic-dressing-for-burn-wounds-100635648",false,"NCT07555418","Cell Suspension With Biologic Dressing for Burn Wounds","A Prospective, Multicenter, Real-World Observational Study of Autologous Epidermal Cell Suspension Combined With Biological Dressing for Wound Repair After Dermabrasion or Surgical Debridement in Patients With Second-Degree Burns","Inclusion Criteria:\n\n* Patients with second-degree burn wounds requiring surgical dermabrasion or debridement and wound repair.\n* Age (No age restriction). For minors under 18 years, informed consent must be provided by a parent or legal guardian.\n* Stable vital signs and able to tolerate debridement and surgical procedures as confirmed by routine examinations.\n* Understand and willing to participate and able to provide signed informed consent.\n\nExclusion Criteria:\n\n* Severe uncontrolled systemic disease or acute systemic infection, or severe organ dysfunction (heart, lung, brain, etc.).\n* Psychiatric disorder that prevents compliance with treatment or follow-up.\n* Known allergy to porcine-derived materials or any component of the cell suspension preparation reagents.\n* Presence of diseases (e.g., autoimmune disease) or use of medications (e.g., high-dose immunosuppressants or corticosteroids) that may significantly affect wound healing.\n* HIV positivity, clinical diagnosis of AIDS, or absolute neutrophil count (ANC) \\\u003C 1000 cells\u002Fmm³ during screening.","ALL",{"count":36,"type":37},386,"ESTIMATED","6 Months","OBSERVATIONAL","This study is a prospective, multicenter, real-world observational study. It aims to evaluate the effectiveness and safety of a combined therapy-autologous epidermal cell suspension followed by biological dressing (porcine xenograft) coverage-for wound repair after dermabrasion or surgical debridement in patients with second-degree burns. A total of 193 patients receiving the combined therapy will be enrolled from multiple hospitals across China. Their outcomes will be compared with 193 matched patients who received conventional treatment alone (e.g., xenograft alone, autologous skin grafting, or standard dressing changes). The primary outcomes include wound healing rate at 4 weeks and time to complete wound closure. Secondary outcomes include scar assessment, pigmentation, functional recovery, quality of life, and safety. Patients will be followed for up to 6 months.",[42],"Wound Healing","NOT_YET_RECRUITING","2026-04-24",{"date":46,"type":47},"2026-04-29","ACTUAL",{"date":49,"type":37},"2026-05-01",{"date":51,"type":37},"2029-12-31",{"name":5,"class":6}]